Ceo
CurrentARIZ Precision Medicine is targeting cancer at the root cause, a genetic error that occurs early in the cancerization of humans. Our lead drug candidate is undergoing proof of concept studies in animal models of lung cancer. We have drug candidates for breast, colon, liver, lung, ovarian and prostate cancer that we will be testing over the next 12-18 months. We have several partnerships already and intend to add a strategic partner to license our cancer drug candidates. We were recently honored by several organizations for our efforts in the cancer field.